EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy

Hung Wei Yang; Yu Jen Lu; Kun Ju Lin; Sheng Chieh Hsu; Chiung Yin Huang; Shu Han She; Hao Li Liu; Chih Wen Lin; Min Cong Xiao; Shiaw Pyng Wey; Pin Yuan Chen; Tzu Chen Yen; Kuo Chen Wei; Chen Chi M. Ma

doi:10.1016/j.biomaterials.2013.06.007

EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy

Hung Wei Yang, Yu Jen Lu, Kun Ju Lin, Sheng Chieh Hsu, Chiung Yin Huang, Shu Han She, Hao Li Liu, Chih Wen Lin, Min Cong Xiao, Shiaw Pyng Wey, Pin Yuan Chen, Tzu Chen Yen, Kuo Chen Wei, Chen Chi M. Ma

Department of Biomedical Engineering

Research output: Contribution to journal › Article › peer-review

130 Citations (Scopus)

Abstract

Low accumulation of chemotherapeutic agent in tumor tissue and multidrug resistance (MDR) present a major obstacle to curing cancer treatment. Therefore, how to combine several therapeutics in one system is a key issue to overcome the problem. Here, we demonstrate epidermal growth factor receptor (EGFR) antibody-conjugated PEGylated nanographene oxide (PEG-NGO) to carry epirubicin (EPI) for tumor targeting and triple-therapeutics (growth signal blocking, chemotherapy, photothermal therapy) in tumor treatment. This synergistic targeted treatment simultaneously enhances the local drug concentration (6.3-fold) and performs the ultra-efficient tumor suppression to significantly prolong the mice survival (over the course of 50 days).

Original language	English
Pages (from-to)	7204-7214
Number of pages	11
Journal	Biomaterials
Volume	34
Issue number	29
DOIs	https://doi.org/10.1016/j.biomaterials.2013.06.007
Publication status	Published - 2013 Sept

All Science Journal Classification (ASJC) codes

Biophysics
Bioengineering
Ceramics and Composites
Biomaterials
Mechanics of Materials

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.biomaterials.2013.06.007

Cite this

@article{1ed13b247b014d3b82463e0c6a2915dd,

title = "EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy",

abstract = "Low accumulation of chemotherapeutic agent in tumor tissue and multidrug resistance (MDR) present a major obstacle to curing cancer treatment. Therefore, how to combine several therapeutics in one system is a key issue to overcome the problem. Here, we demonstrate epidermal growth factor receptor (EGFR) antibody-conjugated PEGylated nanographene oxide (PEG-NGO) to carry epirubicin (EPI) for tumor targeting and triple-therapeutics (growth signal blocking, chemotherapy, photothermal therapy) in tumor treatment. This synergistic targeted treatment simultaneously enhances the local drug concentration (6.3-fold) and performs the ultra-efficient tumor suppression to significantly prolong the mice survival (over the course of 50 days).",

author = "Yang, {Hung Wei} and Lu, {Yu Jen} and Lin, {Kun Ju} and Hsu, {Sheng Chieh} and Huang, {Chiung Yin} and She, {Shu Han} and Liu, {Hao Li} and Lin, {Chih Wen} and Xiao, {Min Cong} and Wey, {Shiaw Pyng} and Chen, {Pin Yuan} and Yen, {Tzu Chen} and Wei, {Kuo Chen} and Ma, {Chen Chi M.}",

note = "Funding Information: We thank the National Science Council of the Republic of China , National Health Research Institutes of Taiwan , and Chang Gung Memorial Hospital , and National Tsing Hua University for financial support ( NSC 101-2120-M-182A-002-CCI , NHRI-EX102-10004NI , CMRPG3A0503 , CMRPG3C0351 , CMRPD1A0233 , CMRPG3A0041, 102N2024E1 , and 102N2772E1 ). The authors thank Dr. Yin-Cheng Huang for his technical assistance, Chang Gung Memorial Hospital Microscopy Core Laboratory and Animal Molecular Imaging Center for assistance with TEM, confocal microscopy and SPECT/CT tomography.",

year = "2013",

month = sep,

doi = "10.1016/j.biomaterials.2013.06.007",

language = "English",

volume = "34",

pages = "7204--7214",

journal = "Biomaterials",

issn = "0142-9612",

publisher = "Elsevier BV",

number = "29",

}

TY - JOUR

T1 - EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy

AU - Yang, Hung Wei

AU - Lu, Yu Jen

AU - Lin, Kun Ju

AU - Hsu, Sheng Chieh

AU - Huang, Chiung Yin

AU - She, Shu Han

AU - Liu, Hao Li

AU - Lin, Chih Wen

AU - Xiao, Min Cong

AU - Wey, Shiaw Pyng

AU - Chen, Pin Yuan

AU - Yen, Tzu Chen

AU - Wei, Kuo Chen

AU - Ma, Chen Chi M.

N1 - Funding Information: We thank the National Science Council of the Republic of China , National Health Research Institutes of Taiwan , and Chang Gung Memorial Hospital , and National Tsing Hua University for financial support ( NSC 101-2120-M-182A-002-CCI , NHRI-EX102-10004NI , CMRPG3A0503 , CMRPG3C0351 , CMRPD1A0233 , CMRPG3A0041, 102N2024E1 , and 102N2772E1 ). The authors thank Dr. Yin-Cheng Huang for his technical assistance, Chang Gung Memorial Hospital Microscopy Core Laboratory and Animal Molecular Imaging Center for assistance with TEM, confocal microscopy and SPECT/CT tomography.

PY - 2013/9

Y1 - 2013/9

N2 - Low accumulation of chemotherapeutic agent in tumor tissue and multidrug resistance (MDR) present a major obstacle to curing cancer treatment. Therefore, how to combine several therapeutics in one system is a key issue to overcome the problem. Here, we demonstrate epidermal growth factor receptor (EGFR) antibody-conjugated PEGylated nanographene oxide (PEG-NGO) to carry epirubicin (EPI) for tumor targeting and triple-therapeutics (growth signal blocking, chemotherapy, photothermal therapy) in tumor treatment. This synergistic targeted treatment simultaneously enhances the local drug concentration (6.3-fold) and performs the ultra-efficient tumor suppression to significantly prolong the mice survival (over the course of 50 days).

AB - Low accumulation of chemotherapeutic agent in tumor tissue and multidrug resistance (MDR) present a major obstacle to curing cancer treatment. Therefore, how to combine several therapeutics in one system is a key issue to overcome the problem. Here, we demonstrate epidermal growth factor receptor (EGFR) antibody-conjugated PEGylated nanographene oxide (PEG-NGO) to carry epirubicin (EPI) for tumor targeting and triple-therapeutics (growth signal blocking, chemotherapy, photothermal therapy) in tumor treatment. This synergistic targeted treatment simultaneously enhances the local drug concentration (6.3-fold) and performs the ultra-efficient tumor suppression to significantly prolong the mice survival (over the course of 50 days).

UR - http://www.scopus.com/inward/record.url?scp=84879605060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879605060&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2013.06.007

DO - 10.1016/j.biomaterials.2013.06.007

M3 - Article

C2 - 23800742

AN - SCOPUS:84879605060

SN - 0142-9612

VL - 34

SP - 7204

EP - 7214

JO - Biomaterials

JF - Biomaterials

IS - 29

ER -

EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this